Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance. - Wikidata - wikimedia - TriplyDB

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

http://www.wikidata.org/entity/Q37018340

about

Global epidemiology and burden of HCV infection and HCV-related disease.Restrictions for reimbursement of direct-acting antiviral treatment for hepatitis C virus infection in Canada: a descriptive study.Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy.Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes Update in HIV-hepatitis C virus coinfection in the direct acting antiviral era.The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation.Real-world challenges for hepatitis C virus medications: a critical overview.Regional differences in treatment rates for patients with chronic hepatitis C infection: Systematic review and meta-analysis.The National Academy Report on the Elimination of Viral Hepatitis: An Infectious Disease Physician's Perspective.Extrahepatic Complications of Hepatitis C Virus Infection in HIV and the Impact of Successful Antiviral Treatment.Vedroprevir in the management of hepatitis C virus infection.Direct-Acting Antivirals Improve Access to Care and Cure for Patients With HIV and Chronic HCV Infection.Barriers to care for chronic hepatitis C in the direct-acting antiviral era: a single-centre experience.Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.Medicaid Reimbursement for Oral Direct Antiviral Agents for the Treatment of Chronic Hepatitis C.Pluripotent Stem Cell-Derived Hepatocyte-like Cells: A Tool to Study Infectious Disease.Increasing success and evolving barriers in the hepatitis C cascade of care during the direct acting antiviral era.Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study.Strategies for the elimination of hepatitis C virus infection as a public health threat in the United States Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men

P2860

Q30240220-93DC4916-DD37-46B9-BFAE-D434FAAE5A3E Q37521046-53DF3DAF-A624-46D9-95C9-36D989A28A63 Q37578288-77DE9A3A-2E74-426E-AFC2-C4CBB6DBC514 Q38602837-32A18607-CCC1-48AE-827F-44E1040C2583 Q38753617-867BBC0A-FA0A-44F1-8A27-45BFB6143251 Q38757351-B4EEE958-E982-4EC3-AA65-E72B357D9881 Q39326974-67456A35-9F1B-43EF-B8E9-ADBAA953E677 Q40064478-7FFE7565-18A3-4DE2-8D50-BB20E293840A Q40175562-B23FBB83-29AE-4DBC-BB18-702F7CBFF2AF Q40341541-7EF03AB2-8A60-41B9-945C-5E4BD7F247D0 Q45325957-354A2A1A-6957-44D9-A242-F5784A829B52 Q47120815-03B70F55-0470-438E-97BC-C696C317876F Q47553765-C2470B4E-A1AA-4552-A687-8F4CE017AEA8 Q47565629-85C5CC30-B0D7-4918-AF2F-316CA71447AD Q53381076-54116F63-4057-4FE7-BCAA-C66127C616DC Q55190764-0D9AF24F-CD3C-484C-A5FB-9F0A8011F1AB Q55239844-2C771333-8D2C-4216-BC6E-6345250A9A25 Q55452535-9C615C0F-3C41-4C03-BC4A-259251F53A19 Q57193075-F59991AF-CC10-49D0-91EC-8B34CBA15111 Q57821930-3423C1EE-62B9-4914-8229-3E9F4FB1C37E

P2860

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

http://www.wikidata.org/entity/Q37018340

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 05 April 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

@en

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

@nl

type

label

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

@en

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

@nl

prefLabel

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

@en

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

@nl

P1433

Q37018340-B2301812-2C01-460A-B93E-9B578AC0BDD7

P1476

Q37018340-3391601E-1FAA-462B-B31D-C35B70E27490

P2093

Q37018340-0A9ABE64-88D5-46E4-A90F-AF7B9B263109

Q37018340-1AFE8A0D-299D-44C3-8E6C-1BF7FEEE3B05

Q37018340-3F6B3986-B7D7-4FD6-A9D1-32D0EF601803

Q37018340-447B8258-8FF7-4156-867C-9DB079D35A53

Q37018340-55620FC9-6525-4EB2-BC6E-F53E7504FED3

Q37018340-68A29B44-2F7E-48D3-BDCD-FCCAF8057E60

Q37018340-68F077CA-3057-4873-8846-36D91D1E5788

Q37018340-89CF900B-7D9A-4EB6-8F52-4C9A2AB37797

Q37018340-9B24FA1F-57F0-4B84-94A8-067680E99CE3

Q37018340-9F5F66A6-1523-4A51-B6F0-D6DFDB46BB11

P2860

Q37018340-0D75EC45-E760-4600-8D8B-3B6ED75ECE94

Q37018340-102C5304-B460-4B85-82EB-4B6384E216CB

Q37018340-1094A705-3BFC-4009-92A2-C49BC0938E52

Q37018340-12351ED1-005F-4D79-B6D2-65D9A04C1D1E

Q37018340-17D0BBDF-B74F-4A5F-8B94-6B4F4CD9C5A6

Q37018340-1F72BB1F-E72B-4E57-853D-4E9C6E9F5C9B

Q37018340-2EE17B37-EA46-42DC-802A-A442F0570F60

Q37018340-3F50EC08-3202-462A-BEF8-595442EC6EFA

Q37018340-4F09DF0D-3932-40C4-B2A3-A98BF9A2F4C2

Q37018340-4F8DB314-FFF2-4DFC-A510-F17CC646DD63

P304

Q37018340-3A5D0243-BB0B-4DA8-8AC2-DAF67BF4D748

P31

Q37018340-9EAA1815-742F-46B6-AFC2-D9DE98EE9CB4

P356

Q37018340-5A5681C4-72EC-440B-AFAD-5EA2CB28B33F

P407

Q37018340-1A5B7D93-D32C-4BBE-9F4C-7652ECA75454

P433

Q37018340-DE5F39F9-F656-43CC-A4C4-4A2EF5531489

P478

Q37018340-B7D2A707-111D-470C-ACF9-709C92E834D2

P50

Q37018340-79C95887-EC50-41FD-B1D3-D3029A275D5F

P577

Q37018340-DC024C83-25E7-4A72-9B05-409C40BD5F32

P5875

Q37018340-6656FEA8-327A-4159-9532-D13A447AB588

P698

Q37018340-A1F4B4B4-BE22-46E0-A0E4-B959A5F5C588

P932

Q37018340-BBED2F49-C945-4EB2-BBF6-451110D2594D

P356

J.CGH.2016.03.040

P1433

Clinical Gastroenterology and Hepatology

P1476

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

@en

P2093

Amanda Binkley

http://www.w3.org/2001/XMLSchema#string

Cassandra Peleckis

http://www.w3.org/2001/XMLSchema#string

Charitha Gowda

http://www.w3.org/2001/XMLSchema#string

Dena M Carbonari

http://www.w3.org/2001/XMLSchema#string

Jalpa A Doshi

http://www.w3.org/2001/XMLSchema#string

Jason A Roy

http://www.w3.org/2001/XMLSchema#string

Jay R Kostman

http://www.w3.org/2001/XMLSchema#string

Jody Gilmore

http://www.w3.org/2001/XMLSchema#string

Joshua T Halladay

http://www.w3.org/2001/XMLSchema#string

Kathryn Battista

http://www.w3.org/2001/XMLSchema#string

P2860

Natural history of hepatitis C

Chronic hepatitis C virus infection and neurological and psychiatric disorders: an overview

A modified poisson regression approach to prospective studies with binary data

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection

Missing Data: How to Best Account for What Is Not Known.

Global distribution and prevalence of hepatitis C virus genotypes.

Association of hepatitis C seropositivity with increased risk for developing end-stage renal disease.

Descriptive analyses of the integrity of a US Medicaid claims database.

The risk of incident coronary heart disease among veterans with and without HIV and hepatitis C

P304

1035-1043

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CGH.2016.03.040

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P50

K. Rajender Reddy

P577

2016-04-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

301239166

http://www.w3.org/2001/XMLSchema#string

P698

27062903

http://www.w3.org/2001/XMLSchema#string

P932

4912853

http://www.w3.org/2001/XMLSchema#string